Bifidobacterium mitigates autoimmune hepatitis by regulating IL-33-induced Treg/Th17 imbalance via the TLR2/4 signaling pathway

• Jianguo Song ^[2] ; Juan Dai ^[3] ; Xueping Chen ^[4] ; Fei Ding ^[3] ; Yanbo Ding ^[3] ; Liang Ma ^[2] ; Liwen Zhang ^[1]
  1. [1] Nanjing Medical University

     Nanjing Medical University

     China

     
  2. [2] The Fifth People’s Hospital of Xinjiang Uygur Autonomous Region, Xin Jiang, China
  3. [3] The First People’s Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, China.
  4. [4] The People’s Hospital of Wuqia, Xinjiang, China

  Mostrar afiliaciones +
• Localización: Histology and histopathology: cellular and molecular biology, ISSN-e 1699-5848, ISSN 0213-3911, Vol. 39, Nº. 5, 2024, págs. 623-632
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • The present work aims to evaluate the efficacy of Live Combined Bifidobacterium, Lactobacillus and Enterococcus Capsules (LCBLECs), a probiotic drug containing Bifidobacterium, in the treatment of autoimmune hepatitis (AIH). In this study, a mouse model of experimental autoimmune hepatitis (EAH) was established to investigate the effects of LCBLECs on AIH. The results showed that LCBLECs improved dysbiosis of gut microbiota, reduced liver injury, restored liver function, and maintained Treg/Th17 balance in EAH mice. In addition, LCBLECs restored Treg/Th17 balance in EAH mice by downregulating IL33 production. Besides, LCBLECs also suppress IL-33 upregulation in EAH mice by inhibiting the TLR2/4 signaling pathway. Furthermore, LCBLECs also mitigated dysbiosis of gut microbiota and enhanced the efficacy of conventional treatment for AIH patients. To sum up, our findings revealed that LCBLECs exerted therapeutic effects on EAH mice by improving Treg/Th17 imbalance in an IL-33-dependent manner via the TLR2/4 signaling pathway and relieved the clinical symptoms of AIH patients, indicating Bifidobacterium supplementation with LCBLECs might be a potential adjuvant therapy for AIH treatment.